Skip to main content

Myasthenia Gravis Market to Witness Comprehensive Growth by 2027


      • According to Transparency Market Research’s latest report on the global myasthenia gravis market for the historical period 2018–2019 and forecast period 2020–2030, high prevalence of autoimmune diseases and strong focus on introducing new therapies is augmenting the growth of global myasthenia gravis market. Moreover, improving healthcare infrastructure is likely boost the growth of global myasthenia gravis market during the forecast period.
      • According to the report, the global myasthenia gravis market was valued at US$ 1.2 Bn in 2018 and is anticipated to expand at a CAGR of 8.0% from 2019 to 2027

      Request the Coronavirus Impact Analysis on this Markets -  https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=26105

      fa global myasthenia gravis market

      To know the scope of our report Get a Sample on Myasthenia Gravis Market

      Rise in Focus on Research & Development and Increase in Prevalence of Autoimmune Disorder: Key Drivers of Global Myasthenia Gravis Market

      • Autoimmune disorder is a condition of immune system in which the body's immune system attacks healthy cells. It is most common in the older men (over 60) and young adult women (under 40). Hence, increase in geriatric population is a key factor likely boost the growth of market. For instance, according to Cancer Facts & Figures 2019, estimated number of older adults age 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060
      • Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects voluntary muscles. According to the Myasthenia Gravis Foundation of America, around 20 in 100,000 people in the U.S. are diagnosed with myasthenia gravis each year
      • Myasthenia gravis is a rare disease without a definite cure, however it can be treated with medications, surgeries, and other therapies alone or in combination. This is augmenting the demand for new therapies and medications, which is driving key players operating in the market to invest in the research and development and develop new therapies. For instance, Rozanolixizumab (UCB7665) is a humanized anti-human neonatal Fc receptor (FcRn) monoclonal antibody designed to reduce the levels of pathogenic IgG in autoimmune diseases. It is in clinical trial phase for reducing the levels of pathogenic IgG in autoimmune diseases and myasthenia gravis. Strong pipeline and introduction of new therapies are the factors likely boost the growth of myasthenia gravis market

      Get a glimpse of the in-depth analysis through our Report Brochure

      Increase in Healthcare Infrastructure Propel Global Myasthenia Gravis Market Growth

      • Increase in health care expenditure coupled with rise in global per capita income is anticipated to drive demand for costly treatments such as plasma exchange and intravenous immunoglobulin (IVIG) therapies
      • Moreover, governments in developing countries are making significant investments toward modernization of health care infrastructure, which is likely to increase access to health care. This is expected to increase in the demand for advance technologies, therapies and treatments. This is leading to create opportunities in the monoclonal antibodies and IVIG treatments in the myasthenia gravis market in the near future

      Buy _ Research Report -   https://www.transparencymarketresearch.com/checkout.php?rep_id=26105&ltype=S

      Expensive Treatment Options to Hamper Global Myasthenia Gravis Market

      • Discovery and development of new therapeutics incurs high cost and takes longer time for commercialization. The never approved therapies with IVIG and monoclonal antibodies are expensive treatment options. The cost of plasma collection and manufacturing processes for IVIG products is high as compared to the materials and processes used in the manufacture of traditional pharmaceutical products. Moreover, being a blood derived component, highly sophisticated collection, purification, and storage methods are required for intravenous immunoglobulin (IVIG) products.
      • Plasmapheresis and thymectomy are costly in comparison to symptomatic drug therapy which additionally need hospitalization. Cost is major factor that influence the selection of treatment which is anticipated to hamper the growth of global myasthenia gravis treatment market.

      Chronic Side Effects: Restrain of Global Myasthenia Gravis Market

      • Side effects associated with intravenous immunoglobulin (IVIG) preparations could present serious health problems in some patients. Some of the side effects associated with intravenous immunoglobulin (IVIG) are flushing, muscle cramps, chills, fever, nausea, vomiting, back/joint pain, chest pain, sudden cough, wheezing, or shortness of breath.
      • These side effects can sometimes force a patient to discontinue the therapy which are leading to restrain the global myasthenia gravis market.

      Global Myasthenia Gravis Market: Competitive Landscape

      • This report profiles major players in the global myasthenia gravis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
      • The global myasthenia gravis market is highly fragmented, with the presence of a number of international as well as regional players
      • Leading players operating in the global myasthenia gravis market are
        • Alexion Pharmaceutical Inc.
        • Avadel Pharmaceuticals, PLC. (Flamel Technologies)
        • CSL Behring
        • Grifols, S.A.
        • Baxter International, Inc.
        • Shire plc
        • Novartis AG
        • F. Hoffmann-La Roche AG
        • Takeda Pharmaceutical Company Limited
        • Valeant Pharmaceuticals International, Inc.

      Expanding operations in future? To get the perfect launch ask for a custom report 

      More Trending Reports by Transparency Market Research –    https://www.biospace.com/article/botulinum-toxin-market-is-projected-to-reach-us-8-718-7-million-by-2026-tmr/

Comments

Post a Comment

Popular posts from this blog

Angioplasty Balloons & Stents Market Research Report | Forecast Until 2027

Complications with Existing Treatments to Drive Innovations The healthcare sector is no stranger to innovations and technological advancements. Research and development activities continue to improve the efficacy of treatments and bring forward new therapies to treat a range of diseases. Over the past couple of decades, minimally invasive procedures have gained a great amount of popularity within the healthcare sector. A similar trend can be observed within the angioplasty balloons & stents market as the adoption of minimally invasive procedures is on the rise, particularly among patients who have been diagnosed with coronary heart diseases or experienced a heart attack. Request Sample Of Report –   https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5627 At present, healthcare experts are focusing on minimizing the complications involved with the percutaneous coronary intervention (PCI) by leveraging the benefits of technology that conti...
Post a Comment
Read more

Autoimmune Disease Diagnostics Market Analysis and Forecast up to 2023

Autoimmune Disease Diagnostics Market – Snapshot When immune system attacks the body mistakenly, then the resulting condition is known as autoimmune disease. Some of the autoimmune diseases are found more commonly in certain ethnicities than others. A case in point is high prevalence of lupus amongst the Hispanic and African-American group of people rather than Caucasians. The global autoimmune disease diagnostics market is estimated to make substantial gains due to rising incidences of autoimmune diseases across the globe. Request Sample Of Report –    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5351 Some of the autoimmune diseases such as lupus and multiple sclerosis run within families. In that case, the family members will inherit vulnerability to the autoimmune illness that runs in the family but might not necessarily be affected by it. Increased Prevalence of Autoimmune Diseases to Spell Growth of the Market Many of the auto...
Post a Comment
Read more

Analysis of COVID-19 Collagen Peptide and Gelatin Market

Collagen Peptide and Gelatin Market: Overview According to Transparency Market Research’s latest report on the global collagen peptide and gelatin market for the historical period  2017–2018  and forecast period  2019–2027 , increase in commercialization of novel collagen-based drug delivery systems and rise in social awareness about personal well-being are projected to drive the global collagen peptide and gelatin market According to the report, the global collagen peptide and gelatin market was valued at  US$ 5,976.9 Mn  in  2018  and is projected to expand at a CAGR of  8.7%  from  2019  to  2027 To know the scope of our report  Get a Sample  on Collagen Peptide and Gelatin Market Increase in social awareness about personal well-being and rigorous research and development activities in regenerative medicine and wound healing: Key Drivers Major factors driving the collagen peptide application in nutrac...
Post a Comment
Read more